Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus ELIXOPHYLLIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus ELIXOPHYLLIN SR.
AMINOPHYLLINE DYE FREE vs ELIXOPHYLLIN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular cAMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Terminal elimination half-life: 7-9 hours in adults (nonsmokers). In smokers, hepatic clearance is increased, reducing half-life to 4-5 hours. In patients with hepatic cirrhosis, half-life may extend to 24 hours. In neonates, half-life is prolonged (20-30 hours).
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Renal: approximately 90% of the dose is eliminated via hepatic metabolism (N-demethylation and hydroxylation), with about 10% excreted unchanged in urine. The primary metabolites are 1-methylxanthine, 1,3-dimethyluric acid, and 3-methylxanthine. Fecal excretion is negligible (<1%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator